Health Utility Analysis of Tepotinib in Patients with Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping.

Mo YangHelene VioixEmma S HookAnthony J HatswellRachael L BattesonBruce R GaumondAurora O'BrateSanjay PopatPaul K Paik

Published in: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research (2023)

In this first analysis of health state utilities in patients with METex14 skipping NSCLC, who received tepotinib, utilities were significantly associated with progression and TTD, but not prior treatment.

Keyphrases

public health
healthcare
mental health
small cell lung cancer
health information
health promotion
tyrosine kinase
advanced non small cell lung cancer
replacement therapy